| Product NDC: | 0597-0001 |
| Proprietary Name: | Aggrenox |
| Non Proprietary Name: | aspirin and dipyridamole |
| Active Ingredient(s): | 25; 200 mg/1; mg/1 & nbsp; aspirin and dipyridamole |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0597-0001 |
| Labeler Name: | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020884 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19991219 |
| Package NDC: | 0597-0001-60 |
| Package Description: | 1 BOTTLE in 1 CARTON (0597-0001-60) > 60 CAPSULE in 1 BOTTLE |
| NDC Code | 0597-0001-60 |
| Proprietary Name | Aggrenox |
| Package Description | 1 BOTTLE in 1 CARTON (0597-0001-60) > 60 CAPSULE in 1 BOTTLE |
| Product NDC | 0597-0001 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | aspirin and dipyridamole |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19991219 |
| Marketing Category Name | NDA |
| Labeler Name | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Substance Name | ASPIRIN; DIPYRIDAMOLE |
| Strength Number | 25; 200 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC] |